Checkmate Pharmaceuticals Announces Full Year 2021 Financial Results and Provides Business Update

Provided By Globe Newswire

Last update: Mar 29, 2022

Alan Bash, experienced biopharmaceutical executive, appointed President and CEO

Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck cancer indications ongoing; Trial dosing initiated in cohorts for PD-1 refractory non-melanoma skin cancers